We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
Cap. Flow
-$473M
Cap. Flow %
-6.14%
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$96.5M
2
UTHR icon
United Therapeutics
UTHR
+$84.1M
3
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$79.6M
4
ZY
Zymergen Inc. Common Stock
ZY
+$64.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$60M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$40.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$39.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$36.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Miscellaneous 11.22%
3 Financials 0.64%
4 Consumer Staples 0.2%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVM icon
151
CEL-SCI Corp
CVM
$26M
– –
-1,123
Closed -$513K
KYNB
152
PUT
Kyntra Bio
KYNB
$31.5M
– –
-8,000
Closed -$6.94M
PCVX icon
153
Vaxcyte
PCVX
$8.81B
– –
-850,000
Closed -$16.8M
PHR icon
154
Phreesia
PHR
$642M
– –
-100,000
Closed -$5.21M
SANA icon
155
Sana Biotechnology
SANA
$946M
– –
-10,000
Closed -$335K
SNDX icon
156
Syndax Pharmaceuticals
SNDX
$1.62B
– –
-270,000
Closed -$6.04M
TXMD icon
157
TherapeuticsMD
TXMD
$25M
– –
-55,000
Closed -$3.69M
VINC
158
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-15,000
Closed -$5.79M
TLIS
159
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-16,667
Closed -$3.21M
VRAY
160
DELISTED
ViewRay, Inc.
VRAY
– –
-751,748
Closed -$3.27M
FMTX
161
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,250,000
Closed -$35M
ARNA
162
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-575,007
Closed -$39.9M
DFHTU
163
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
– –
-300,000
Closed -$3.93M
VINCW
164
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
– –
-300,000
Closed -$1.21M
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.

  • Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
  • Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
  • Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
  • Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
  • Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
  • Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
  • Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.